Emerging targeted therapies in triple-negative breast cancer.

@article{Crown2012EmergingTT,
  title={Emerging targeted therapies in triple-negative breast cancer.},
  author={John P. A. Crown and Judy O'Shaughnessy and Giuseppe Gullo},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2012},
  volume={23 Suppl 6},
  pages={vi56-65}
}
Standard chemotherapy regimens can prove effective for patients with early triple-negative breast cancer (TNBC); however, patients with advanced disease typically respond poorly and rapidly progress, and the outcome is poor. New targeted therapies are therefore an urgent unmet medical need for this patient population. Translational and clinical studies into new TNBC treatments have been facilitated by the increased understanding of the aberrant signal transduction pathways regulating growth and… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 77 extracted citations

Triple-negative breast cancer: what is known about it?

Clinical journal of oncology nursing • 2014
View 6 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 76 references

The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2011
View 3 Excerpts
Highly Influenced

A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology • 2011

Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2011
View 1 Excerpt

Similar Papers

Loading similar papers…